Literature DB >> 18209967

[Patient with heparin-induced thrombocytopenia type II and implanted left ventricular assist device].

J T Lutz1, H J Exner, A Schannewitzky, W Fehske, K Görlinger.   

Abstract

The administration of heparin can lead to life-threatening heparin-induced thrombocytopenia (HIT) type II, which is caused by antibodies against heparin-platelet factor 4-complexes. The multimorbid patient presented here suffered from HIT II. Preoperative and postoperative prevention of thrombosis was successfully conducted with argatroban and the management of anticoagulation is presented. During therapy with argatroban, discrepancies in the partial thromboplastin time (PTT) and the international normalized ratio (INR) appeared sporadically. The clinical causes for these differences remain unclear.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209967     DOI: 10.1007/s00101-007-1297-3

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  8 in total

1.  Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.

Authors:  S B Sheth; R A DiCicco; M J Hursting; T Montague; D K Jorkasky
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.

Authors:  S K Swan; M J Hursting
Journal:  Pharmacotherapy       Date:  2000-03       Impact factor: 4.705

3.  Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure.

Authors:  Ortrud Vargas Hein; Christian von Heymann; Stanislao Morgera; Wolfgang Konertz; Sabine Ziemer; Claudia Spies
Journal:  Artif Organs       Date:  2005-06       Impact factor: 3.094

4.  Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia.

Authors:  D E Wallis; R Quintos; W Wehrmacher; H Messmore
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

5.  Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use.

Authors:  Norbert Lubenow; Sixten Selleng; Hans-Georg Wollert; Petra Eichler; Bernd Müllejans; Andreas Greinacher
Journal:  Ann Thorac Surg       Date:  2003-02       Impact factor: 4.330

6.  [Informed consent on heparin-induced thrombocytopenia during thrombosis prophylaxis. A pilot study including 460 patients].

Authors:  P Hinz; N Lubenow; A Ekkernkamp; A Greinacher
Journal:  Dtsch Med Wochenschr       Date:  2003-10-17       Impact factor: 0.628

7.  Argatroban anticoagulation in critically ill patients.

Authors:  Martin Beiderlinden; Tanja A Treschan; Klaus Görlinger; Jürgen Peters
Journal:  Ann Pharmacother       Date:  2007-04-17       Impact factor: 3.154

8.  Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.

Authors:  David R Williamson; Isabelle Boulanger; Mariline Tardif; Martin Albert; Geneviève Grégoire
Journal:  Pharmacotherapy       Date:  2004-03       Impact factor: 4.705

  8 in total
  1 in total

1.  Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia.

Authors:  Felicitas Stoll; Miriel Gödde; Albrecht Leo; Hugo A Katus; Oliver J Müller
Journal:  Clin Cardiol       Date:  2018-12-03       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.